Global Gastroenteritis Treatment Market

Global Gastroenteritis Treatment Market Size Insights Forecasts to 2035

• The Global Gastroenteritis Treatment Market Size Was Estimated at USD 41.11 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.79 % from 2025 to 2035
• The Worldwide Gastroenteritis Treatment Market Size is Expected to Reach USD 76.33 Billion by 2035
• North America is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Gastroenteritis Treatment Market Size Was Worth Around USD 41.11 Billion In 2024 And Is Predicted To Grow To Around USD 76.33 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 5.79 % From 2025 To 2035. The market is undergoing significant growth due to the rising incidence of gastrointestinal disorders like acid reflux, irritable bowel syndrome, and Crohn's disease. In addition, the growing awareness about gastrointestinal health and the increasing demand for convenient and effective solutions are some of the most important factors contributing to the growth of the market. Moreover, the rising number of gastrointestinal disorders due to the ageing population and dietary changes is also an important factor.

 

Market Overview

The worldwide gastroenteritis treatment market is the sector for treatments, medications, and supportive products for the management of gastroenteritis, which is the inflammation of the stomach and intestines, often accompanied by symptoms of diarrhoea, vomiting, and dehydration. The market includes medications such as antibiotics for bacterial infections, antiemetics, and biologics. Gastroenteritis, also known as stomach flu, is referred to as an inflammatory disease of the gastrointestinal tract, comprising the stomach and small intestine. It is caused by a virus, bacteria, or parasites and can be transmitted by contaminated food or water. There is no appropriate complete treatment for gastroenteritis, and thus, prevention is the only treatment. Symptoms include vomiting, nausea, cramps and muscle pain. The prevalence of this disease is increasing, and key diagnostic processes and treatments will stimulate the growth of the market.

 

Evidence emerging indicates that norovirus infection is linked with intestinal inflammation and malnutrition and can lead to long-term morbidity. According to the WHO, approximately 685 Million cases of norovirus infection occur every year, including 200 million cases in children under 5 years of age. The impact of norovirus infection is large; norovirus infection leads to an estimated 200,000 deaths every year, including 50,000 child deaths, mainly in low-income countries. The cost of norovirus infection has been estimated at USD 60 Billion.

 

Sun Pharmapartnered with Japan’s Takeda to introduce Vonoprazan (brand name Voltapraz) in India, a novel gastrointestinal (GI) drug targeting acid-peptic disorders such as reflux esophagitis. This collaboration addresses India’s large GI disease burden (affecting 30% of the population) and taps into the booming global GI drug market valued at USD 42 Billion.  

 

Report Coverage

This research report categorises the gastroenteritis treatment market based on various segments and regions, forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the gastroenteritis treatment market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the gastroenteritis treatment market. 

    

Driving Factors  

The gastrointestinal treatment market is fueled by the growing number of cases of Crohn’s disease, ulcerative colitis, and IBD, which affect millions of people worldwide. The awareness and expenditure on healthcare are also driving the demand for advanced treatments. Heavy R&D investments have resulted in the approval and launch of new biologics and small molecules, such as ustekinumab, vedolizumab, and tofacitinib, which provide targeted treatment. Biologics have shown long-term effectiveness, and surgeries, hospitalisations, and emergency visits have been reduced significantly, thereby increasing demand. Partnerships between generic and branded pharmaceutical companies after the expiration of patents are also increasing access to affordable treatments. The gastrointestinal treatment market is a rapidly growing and opportunity-filled area due to the presence of supportive regulatory environments, increasing clinical trials, and a growing preference for minimally invasive treatments.

 

The market for gastrointestinal treatment is growing owing to the increasing number of cases, with the CDC estimating that 1-1.3 million Americans are affected by IBD, and cases of Crohn’s disease and ulcerative colitis are 201 and 238 per 100,000 adults, respectively. This has led to the rapid development of new drugs and their launches in the market, such as mongersen, tofacitinib, ustekinumab, and vedolizumab, which is rapidly becoming a first-line biologic for Crohn’s disease. The biologics have shown a high level of efficiency, leading to a decrease of 40% in surgeries, 60% in ER visits, and 50% in hospitalisations.

 

Restraining Factors  

High costs involved in the production of drugs and R&D of vaccines, drugs, and kits are hindering the growth of the gastroenteritis treatment market. Moreover, the lack of advanced treatment facilities, especially in underdeveloped nations, is also hindering the treatment of severe patients.

 

Market Segmentation    

The gastroenteritis treatment market share is classified into treatment and route of administration.     

 

• The dehydration therapy segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.        

Based on the treatment, the gastroenteritis treatment market is divided into antibiotic therapy, dehydration therapy, and others. Among these, the dehydration therapy segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Dehydration therapy is the largest and most important segment of the gastroenteritis treatment market, led by the global need for fluid replacement in viral and bacterial infections. Oral Rehydration Solutions (ORS) and IV fluids are the leading products in this segment, aided by global health programs and acceptance in developed and developing markets.

 

• The oral segment accounted for the highest market share in 2024 and is projected to grow at a notable CAGR during the forecast period.      

Based on the route of administration, the gastroenteritis treatment market is segmented into oral and parenteral. Among these, the oral segment accounted for the highest market share in 2024 and is projected to grow at a notable CAGR during the forecast period. The oral segment of the gastroenteritis treatment market basically encompasses oral rehydration therapy (ORS) and oral medications (including probiotics, antidiarrheals, and antibiotics for bacterial gastroenteritis). This segment is of utmost importance since oral treatment is the first choice for most cases of gastroenteritis.

Regional Segment Analysis of the Gastroenteritis Treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

Asia Pacific is anticipated to hold the largest share of the gastroenteritis treatment market over the predicted timeframe.     

Asia Pacific is anticipated to hold the largest share of the gastroenteritis treatment market over the predicted timeframe. The Asia Pacific market is expected to be the growing substantial due to the increasing healthcare expenditure, growing awareness about gastrointestinal health, and the rising population affected by lifestyle-related disorders such as obesity and gastrointestinal disorders. Countries like China and India are witnessing a significant rise in the demand for novel gastrointestinal treatments due to their large population base and improving healthcare infrastructure.

 

For example, in August 2022, Bayer AG launched Iberogast, a product developed using medicinal plants that work to rapidly relieve a variety of gastrointestinal symptoms, including abdominal pain, cramps, heaviness, bloating, gas, and nausea. This product launch is a result of the increasing attention towards effective gastrointestinal solutions that cater to the needs of the Asia Pacific population. Moreover, government efforts to improve access to healthcare and emphasise preventive healthcare are also contributing to the growth of the market in the Asia Pacific region.

 

North America is expected to grow at a rapid CAGR in the gastroenteritis treatment market during the forecast period. North America highlights the regional market in 2024 at the global level due to the large number of cases of gastrointestinal disorders like gastroesophageal reflux disease (GERD) and inflammatory bowel disease (IBD). The well-developed healthcare infrastructure, along with a focus on R&D, makes it easier to launch new and innovative gastrointestinal products that cater to the needs of patients. In addition, the growing awareness of gastrointestinal health among the population, along with the rising demand for preventive healthcare, also helps the market grow.

 

A new Canadian clinical trial has proven that ondansetron, when given both in the emergency department and at home, is an effective treatment for vomiting caused by childhood gastroenteritis. This removes much of the guesswork for clinicians and parents, ensuring faster recovery and fewer hospital returns.

 

Competitive Analysis:   

The report offers the appropriate analysis of the key organisations/companies involved within the gastroenteritis treatment market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.  

 

List of Key Companies

• Amgen Inc.
• AstraZeneca
• F. Hoffmann-La Roche Ltd.
• GSK plc
• Hainan Poly Co. Ltd
• Johnson & Johnson Private Limited
• Lilly
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• WOCKHARDT
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

 

Recent Development

 

• In December 2025, Cocrystal Pharma received IRB approval from Emory University School of Medicine to begin a Phase 1b human challenge study of its oral antiviral candidate CDI-988 for norovirus prevention and treatment, with subject enrollment expected in Q1 2026. This marks a major milestone since there are currently no approved treatments or vaccines for norovirus.

 

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the gastroenteritis treatment market based on the following segments: 

  

Global Gastroenteritis Treatment Market, By Treatment

• Antibiotic Therapy
• Dehydration Therapy
• Others

 

Global Gastroenteritis Treatment Market, By Route of Administration

• Oral
• Parenteral

 

Global Gastroenteritis Treatment Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

1. What is the current size of the global gastroenteritis treatment market?

The market was valued at USD 41.11 billion in 2024.

 

2. What is the projected market size by 2035?

It is expected to reach USD 76.33 billion by 2035.

 

3. What is the forecasted CAGR for 2025-2035?

The market is projected to grow at a CAGR of 5.79%.

 

4. What are the main treatment segments?

The market is segmented by treatment into antibiotic therapy, dehydration therapy, and others.

 

5. Which route of administration leads the market?

The oral segment held the highest share in 2024 and is expected to grow notably.

 

6. Which region will dominate the market?

Asia Pacific is anticipated to hold the largest share due to rising healthcare needs and population growth.

 

7. Which region is expected to grow the fastest?

North America is projected to grow at the fastest CAGR, driven by advanced healthcare and high disorder prevalence.

 

8. Who are some key players in the market?

Major companies include Pfizer Inc., Johnson & Johnson, Novartis AG, Sun Pharmaceutical, and AstraZeneca.